NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Thanks Lykiri. If I remember correctly, at 3/17, of the last 108 enrolled, 40 survivors were on trial about 18-24 months and 22 survivors were on trial 24-30 months. If I remember correctly, the enlarged survival curve and censor ticks (prepared by you, Senti et al.) suggested to me that the median time on trial for all 62 survivors was closer to perhaps 22 months. That would also be logical because about twice the number of survivors (40) were 18-24 months on trial than the number (22) that were 24-30 months on trial. A 57.4% survival (62 of 108) at 22 months could of course suggest that at 24 months the survival rate could still be over 50% but not by much.

Even if the survival rate at 24 months was let's say 52%, the fact that it was still 38.9% at 36 months is quite interesting if one takes into consideration that about 46% of the first 223 patients survived at 24 months and only about 23% became post 36 months survivors.